Expanding its offering for Multiple Myeloma and AL Amyloidosis Testing LISSES, France — Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the FLC Kappa […] Read The Rest at :